Results 131 to 140 of about 37,561 (261)

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Pouch Surgery for Ulcerative Colitis: Navigating Complexity in the Modern Era

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) remains the preferred surgical treatment for patients with ulcerative colitis (UC) who require surgery but wish to avoid a permanent ileostomy. Since its introduction in 1978, IPAA has undergone continuous refinement in response to advances in both medical therapy and ...
Gabriele Bislenghi, Caroline Nordenvall, Anthony de Buck van Overstraeten, Peter Kienle, Alaa El‐Hussuna   +4 more
wiley   +1 more source

Challenges in Diagnosing Intrahepatic Cholangiolithiasis in a 39-Year-Old Patient

Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Aim: to highlight the challenges of diagnosing and treating a patient with severe intrahepatic cholangiolithiasis.Key points. Primary sclerosing cholangitis is a chronic progressive liver disease characterized by destructive inflammation and fibrosis in ...
A. K. Guseva, O. N. Sergeyeva, T. P. Nekrasova, O. T. Imaraliev, A. V. Okhlobystin, Y. N. Shirokova, A. S. Ostrovskaya, M. S. Zharkova, A. S. Cherenda, V. T. Ivashkin   +9 more
doaj   +1 more source

Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Elafibranor 80 mg/day is approved for second‐line primary biliary cholangitis (PBC) treatment. We present pharmacokinetic (PK) analyses of elafibranor and its metabolite, GFT1007, and pharmacokinetic‐pharmacodynamic (PKPD) analyses describing the relationship between their exposure and responses in alkaline phosphatase (ALP) and total ...
Qing Xi Ooi, Karl Brendel, Stijn van Beek, Jurij Aguiar Zdovc, Maddlie Bardol, Marion Dehez   +5 more
wiley   +1 more source

Primary sclerosing cholangitis [PDF]

Hepatology, 1999
P, Angulo, K D, Lindor
openaire   +2 more sources

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Intrahepatic bile duct strictures in a liver allograft recipient mimicking recurrent primary sclerosing cholangitis - Follow-up of a case report [PDF]

, 1991
Demetris, AJ, Gordon, R, Hartman, GG, Lerut, J, Starzl, TE   +4 more
core   +1 more source

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 10, Page 1369-1379, May 2026.
Patients who received immune checkpoint inhibitors before liver transplant for the treatment of hepatocellular carcinoma had rejection and survival outcomes comparable to those without ICI exposure. Most rejection episodes were effectively managed with medical therapy.
L. Aceituno, C. Magyar, P. Tabrizian, R. Marino, K. Watt, D. Chascsa, G. Schnickel, V. Banz, F. Alconchel, Celia Martagon, C. Moctezuma, T. Baker, C. Nwaduru, F. J. Krendl, R. Oberhuber, L. Ruiz‐Ortega, C. Demers, R. Bucur, G. O'Kane, A. Vogel, B. Mínguez, G. Sapisochin   +21 more
wiley   +1 more source

Coexisting Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Overlapping Challenges in Diagnosis and Treatment

Case Reports in Gastroenterology
Introduction: Hepatobiliary overlap syndromes describe the coinciding presentation of more than one immune-mediated biliary and liver disease in a single patient and present complex challenges in diagnosis and treatment.
Hannah W. Fiske, Firrah Saeed, Christopher Ward, Boris Sinayuk, Veronica Ulici, Michael Curry, Edward Feller, Samir A. Shah   +7 more
doaj   +1 more source

Associations between use of aspirin and magnetic resonance imaging‐derived liver fat and fibroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3895-3902, May 2026.
Abstract Background The effects of aspirin on hepatic steatosis and fibroinflammation are unclear. The study aimed to examine the association between aspirin use and liver magnetic resonance imaging (MRI)‐derived liver fat and corrected T1 (cT1). Methods We used UK Biobank imaging cohort data.
Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Jun Liu, Mark Woodward   +4 more
wiley   +1 more source